An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of RM-493, a MC4R Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation
Phase of Trial: Phase II/III
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Rhythm
- 09 Apr 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 09 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 10 Jun 2017 Biomarkers information updated